Research programme: AOC3 protein inhibitors - Faron/Priaxon

Drug Profile

Research programme: AOC3 protein inhibitors - Faron/Priaxon

Alternative Names: Farbetic; FP-1101; FP-1102; Vitamin B1 analogues

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Faron Pharmaceuticals; Priaxon
  • Class Small molecules; Vinca alkaloids
  • Mechanism of Action AOC3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Vascular disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Vascular-disorders in Finland (PO)
  • 15 Jun 2010 Early research in Vascular disorders in Finland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top